USD $1426.86
Visudyne is a prescription medication used primarily in the treatment of certain types of macular degeneration, a condition that affects the central part of the retina and can lead to vision loss. It is often used in combination with photodynamic therapy (PDT) to help slow the progression of visual impairment. Visudyne is specially formulated for injection and works by targeting abnormal blood vessels in the eye.
Visudyne (verteporfin) is a photosensitizing agent used in photodynamic therapy to treat abnormal blood vessels in the eye, particularly in patients with wet age-related macular degeneration (AMD) and other conditions like pathologic myopia and ocular histoplasmosis. It is injected into a vein and then activated by a special light that targets the abnormal vessels, leading to their destruction.
Drug Class: Photosensitizing Agent
Categories:
The active ingredient in Visudyne is verteporfin. This compound becomes activated when exposed to a specific type of light, producing reactive oxygen that targets and destroys abnormal blood vessels in the eye.
Visudyne works through a process known as photodynamic therapy. After intravenous injection, verteporfin accumulates in the abnormal blood vessels in the eye. When these areas are exposed to non-thermal red light, verteporfin becomes activated, producing reactive oxygen species that damage the vascular endothelium and occlude the abnormal vessels. This helps to prevent further leakage and growth, thereby slowing the progression of vision loss.
Visudyne is administered by a healthcare professional. It is injected into a vein in the arm, followed by a 15-minute waiting period before the affected eye is treated with a non-thermal laser. The laser activates the medication in the eye, targeting abnormal blood vessels. This procedure usually takes place in a specialized clinical setting.
1. How long does Visudyne stay in the body? Visudyne remains active in the body for about 24 to 48 hours. During this period, you should avoid direct sunlight and bright indoor lights to prevent photosensitivity reactions.
2. Is Visudyne effective for all types of macular degeneration? No, Visudyne is primarily effective for the treatment of wet age-related macular degeneration (AMD) and certain other conditions involving abnormal blood vessels in the eye. It is not used for the dry form of AMD.
3. Can I go outside after Visudyne treatment? You should avoid direct sunlight and bright indoor lights for at least 48 hours after treatment. If you need to go outside, wear protective clothing and sunglasses.
4. What should I do if I experience severe pain during Visudyne infusion? Inform your healthcare provider immediately if you experience severe pain or any other unusual symptoms during the infusion.
5. How often do I need Visudyne treatment? The frequency of Visudyne treatments depends on your individual condition and response to therapy. Your eye doctor will determine the appropriate treatment schedule for you.
6. Is Visudyne covered by insurance? Coverage for Visudyne varies depending on your insurance provider and specific plan. Contact your insurance company to find out if Visudyne is covered under your policy.
7. Are there any long-term side effects of Visudyne? Long-term side effects are rare, but some patients may experience changes in vision. Regular follow-up with your eye doctor is important to monitor for any long-term effects.
Health Guides

Nov 03, 2026
Insulin injection sites should rotate with every dose, using a different point within a planned body area. Home injections go into subcutaneous fat under the skin, not into muscle or a vein. Repeated injections into one spot can cause lipohypertrophy, a fatty lump that makes the insulin absorption r

Nov 02, 2026
ADHD medication monitoring tracks blood pressure, heart rate, body mass, appetite and sleep before treatment, during dose adjustments and throughout long-term care. For adults, NICE recommends pulse and blood pressure checks before and after each dose change, then every six months. The aim is to pre

Oct 31, 2026
Whether to repeat a dose of an oral medication depends on the medicine, formulation, and elapsed time. Vomiting within 15 minutes or seeing an intact tablet can justify considering a replacement; after an hour, another dose is usually unnecessary. These are general timing guides, not permission to r

Oct 30, 2026
Tacrolimus monitoring measures the tacrolimus level in whole blood to help balance organ rejection prevention against drug-related toxic effects. The result is useful only when interpreted against the dose and formulation. A routine trough sample is collected immediately before the next dose, usuall

Oct 28, 2026
Lithium monitoring combines timed blood levels with kidney, thyroid, and calcium tests to keep bipolar treatment effective and reduce toxicity risk. Testing starts before treatment and continues throughout it. Lithium has a narrow therapeutic index, so relatively small changes in blood concentration

Oct 22, 2026
Parkinson's disease medications improve movement by replacing dopamine, stimulating its receptors, or slowing its breakdown. Carbidopa-levodopa remains the most effective treatment for movement symptoms, while other medicines address milder symptoms, wearing-off, or involuntary movements. Treatment

Oct 20, 2026
Methimazole for hyperthyroidism reduces excess thyroid hormone production without destroying the thyroid gland. Treatment usually starts with a higher dose, followed by blood-test-guided reductions as hormone levels return to normal. This guide to methimazole hyperthyroidism treatment covers testing

Oct 19, 2026
Atrial fibrillation medications address three goals: rate control for a fast heart rate, rhythm control for an abnormal rhythm, and stroke prevention with anticoagulants that reduce blood clots. For atrial fibrillation, the regimen depends on stroke risk, heart and kidney function, and other prescri

Oct 16, 2026
SGLT2 inhibitors lower blood glucose by helping the kidneys remove glucose through urine. Selected medicines also reduce heart-failure events and slow chronic kidney disease progression, so prescribing decisions extend beyond blood sugar alone. The short answer: SGLT2 inhibitors can benefit people

Oct 14, 2026
Rheumatoid arthritis medications control inflammation, relieve symptoms, and help prevent joint damage. Methotrexate is a common first-choice disease-modifying drug for people newly diagnosed with moderate or high disease activity. RA has no cure, so treatment usually continues throughout life, thou
